Clario publishes roadmap for using artificial intelligence (AI) to improve patients’ experience in decentralized clinical trials (DCTs)
Manuscript published in Nature Medicine explores how AI practices can benefit participants and improve the quality and accuracy of data collected in clinical trials
PHILADELPHIA, PA – October 20, 2022 – Clario, a technology company that delivers the leading endpoint solutions for decentralized, hybrid and site-based clinical trials, today published a manuscript in Nature Medicine that outlines how AI can improve patients’ experience in DCTs. This comes as remote trials continue to rise in popularity, placing increased responsibility on participants. The study explores how AI automation can support improvements in digital health user interfaces.
“AI is being used to enhance user experience in customer-facing applications across many industries,” said Kevin Thomas, Ph.D., Director of Artificial Intelligence at Clario, one of the researchers. “Adopting this approach in clinical trials means we can help more patients to enroll, empower them to complete trials without undue burden, and ensure they are able to submit high-quality health assessments throughout their participation.”
In the study, Thomas and coauthor Łukasz Kidziński, Ph.D., also Director of Artificial Intelligence at Clario, suggest the following domains of AI can be leveraged to enhance customer experience in clinical trials:
- Reinforcement learning, which is used to optimize notifications on social media platforms, can customize notifications for each participant, helping participants fit eCOA tasks into their schedule while minimizing unhelpful alerts.
- Computer vision enables automatic assessment of images and videos and is used by many mobile banking apps in the U.S. to coach customers on how to photograph their checks for electronic deposits. If deployed in clinical trials, it could empower users to quickly and successfully submit their medical photos and avoid having to retake them.
- Temporal data AI models can be used in mobility trials that rely on wearable sensors, which can be time-consuming for participants to put on, require live guidance, and remain error-prone. These models could be trained to infer how one body part moves based on data collected at a different body part, in some cases enabling participants to replace a full-body array of sensors with a single sensor.
“Asking participants to engage in time-consuming data entry tasks and unintuitive image capturing can reduce their adherence to a trial’s protocols or increase the number of errors they make,” said Kidziński. “AI can address these challenges and reduce the time required for post-hoc central quality control.”
Clario has been developing its AI capabilities since its acquisition of Saliency in 2020 pairing automation with expert human oversight throughout the clinical trial lifecycle. Visit Clario’s website to learn more about its work with AI and how it is helping to transform clinical trials.
To read the full study, visit Nature Medicine.
Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Clario’s global team of science, technology and operational experts have helped deliver more than 27,000 trials and contributed to over 500 FDA and EMEA new drug approvals involving more than seven million participants in over 100 countries. Our innovation has been transforming clinical trials for 50 years.
Clario Media Contact
Snr. Director, Content and Communications
+44 7307 533 162